Anzeige
Meldung des Tages: Gold über 4.862 USD – auf dem Weg zu 5.000 USD: Warum A2 Gold jetzt in eine neue Liga aufsteigt

BioMarin Pharmaceutical Aktie News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN Branche:  Biotechnologie Land:  USA
57,01 $
+0,70 $
+1,24%
48,678 € 16:24:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,78 Mrd. €
Streubesitz
1,13%
KGV
16,80
Index-Zuordnung
Nasdaq Composite Index
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,62: MM5RCV
Werbung

BioMarin Pharmaceutical News

13.01.26 Wirtschaftswoche
BörsenTag: So teuer sind die Rüstungsaktien
Die schwierigste aller Börsenfragen: Soll ich dem Trend folgen, bis zum Ende und darüber hinaus – oder konträr handeln und ungeliebte Papiere kaufen? Überlegungen zu TKMS, ...
12.01.26 - PR Newswire
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
BioMarin Appoints Arpit Davé Chief Digital and Information Officer PR Newswire
09.01.26 - PR Newswire
Veeva und BioMarin schließen langfristige strategische Partnerschaft
Veeva und BioMarin schließen langfristige strategische Partnerschaft PR Newswire
08.01.26 - PR Newswire
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA PR Newswire
08.01.26 - PR Newswire
Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva and BioMarin Form Long-Term Strategic Partnership PR Newswire
08.01.26 - PR Newswire
Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva and BioMarin Form Long-Term Strategic Partnership PR Newswire
19.12.25 - PR Newswire
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook PR ...
11.11.25 - PR Newswire
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England PR Newswire
29.10.25 - PR Newswire
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-​pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with ...
27.10.25 - PR Newswire
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update PR Newswire
22.10.25 - PR Newswire
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET PR Newswire
08.09.25 - PR Newswire
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting PR Newswire
06.09.25 - PR Newswire
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of ...
27.08.25 - PR Newswire
BioMarin to Participate in Upcoming Investor Conferences
BioMarin to Participate in Upcoming Investor Conferences PR Newswire
04.08.25 - PR Newswire
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS PR Newswire
01.08.25 - PR Newswire
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
BioMarin Announces Appointment of Ian T. Clark to Board of Directors PR Newswire
22.07.25 - PR Newswire
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET PR Newswire
01.07.25 - PR Newswire
BioMarin Announces Completion of Acquisition of Inozyme
BioMarin Announces Completion of Acquisition of Inozyme PR Newswire
24.06.25 - PR Newswire
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-​rvox) at International Society on Thrombosis ...
16.05.25 - PR Newswire
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma PR Newswire

Newssuche

Videos

newspaper
20.01.26 +4,75%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »